Epitan receives marketing approval for Zindaclin
By Ruth Beran
Tuesday, 08 November, 2005
Tuesday, 08 November, 2005
Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.
Zindaclin is a once-a-day clindamycin-based gel which Epitan's wholly-owned subsidiary Epipharm in-licensed from UK-based Pro-Strakan Pharmaceuticals (formerly Strakan) in July 2004. The product was submitted for registration from the TGA soon after.
Related News
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
